Delcath Systems Inc., an interventional oncology company specializing in the treatment of primary and metastatic liver cancers, has reported its financial results for the first quarter ended March 31, 2025. The company achieved a total revenue of $19.8 million, a significant increase from $3.1 million in the same period of 2024. This growth was driven by the HEPZATO KIT™, which generated $18.0 million in revenue compared to $2.0 million in the prior year, and CHEMOSAT® revenue, which rose to $1.8 million from $1.1 million. Delcath reported a net income of $1.1 million for the first quarter of 2025, contrasting with a net loss of $11.1 million in the corresponding quarter of the previous year. The company's gross margins improved to 86%, up from 71% in the first quarter of 2024. Selling, general, and administrative expenses for the quarter increased to $11.3 million from $8.8 million in the same period last year, largely due to ongoing commercial expansion efforts including marketing-related costs and the addition of personnel to the commercial team. The company's non-GAAP adjusted EBITDA was $7.6 million, reversing an adjusted EBITDA loss of $7.3 million in the first quarter of 2024. As of March 31, 2025, Delcath had $58.9 million in cash and investments, with no debt reported.